Earnings
The company’s pipeline was strengthened in the second quarter with three strategic collaborations in immuno-oncology, immuno-neurology, and HIV.
The Cambridge-based company is targeting the DNA Damage Response (DDR) pathway to attack various cancers.
It’s been a long season of acquisitions for PerkinElmer. Now in its largest purchase ever, the Massachusetts-based company is dropping a massive $5.25 billion in cash and stock to buy biomedical research tool company BioLegend.
The company also issued an open letter to the Alzheimer’s disease community from Alfred Sandrock, which attempts to push back against negative media attention.
For the past year, Abbott Laboratories and Quest Diagnostics saw their revenue driven by COVID-19 diagnostics, but that seems to be changing as more and more vaccinated individuals are seeking medical advice for non-viral related issues.
Medtech company HeartFlow is heading to the New York Stock Exchange through a merger with special purpose acquisition company, Longview Acquisition Corp. II.
The amount is intended to support the company’s growing portfolio of RNA technologies and accelerate efforts to develop various treatment approaches in the gene therapy field.
In an interview with BioSpace, CEO Victoria Richon expressed her excitement about investor support and developing novel, first-in-class treatments.
Kriya Therapeutics, based in Redwood City, Calif. and Research Triangle Park, NC, closed on a Series B financing worth $100 million.
Through its OrbNet platform, Entos has already forged various partnerships with investors and leaders in the pharmaceuticals, materials, and chemicals industries.
PRESS RELEASES